CHNR vs GLTO Comparison

China Natural Resources Inc is an investment holding company. It principally engaged in the exploration and mining and wastewater treatment businesses in the People's Republic of China. The company has two operating segments: (i) Wastewater treatment segment, which consists of sales of assembled equipment, provision of construction service, and participation in PPP projects as an operator (ii) Exploration and mining segment, which consists of the exploration of lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and the trading of copper ores products. It earns the majority of its revenue from the Wastewater treatment segment.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.